Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Alan Newman who wrote (4535)	6/11/1998 10:18:00 AM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

Headline: Zonagen to Receive $5 Million Milestone Payment From Schering-Plough ====================================================================== THE WOODLANDS, Texas--(BW HealthWire)--June 11, 1998--Zonagen Inc. (NASDAQ:ZONA)(Pacific:ZNG) today announced that Schering-Plough Corporation has agreed to pay to Zonagen an accelerated milestone of $5 million for Vasomax(TM), Zonagen's oral treatment for male erectile dysfunction. Under the terms of the License Agreement, this milestone marks the completion of a clinical program that will be used in support of a New Drug Application (NDA). A July 1998 submission to the FDA is anticipated. In November 1997 Schering-Plough Corporation and Zonagen signed an exclusive worldwide marketing agreement for Vasomax(TM) for the treatment of male erectile dysfunction. Zonagen Inc. specializes in products and services for management of reproductive health. Its technologies focus on the areas of urology, female health and contraception. Through its wholly owned subsidiary, Fertility Technologies Inc. (FTI), Zonagen sells devices, instruments and supplies to the fertility specialist and the OB/GYN. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to those relating to the Company's early stage of development, clinical trial results and FDA approval, substantial dependence on one product, history of operating losses, future capital needs and additional funding, ability to protect patents and proprietary technology, litigation, governmental regulation, limited sales and marketing experience and dependence on collaborators, limited manufacturing capabilities and reliance on third-party manufacturers, competition and technological change, product liability and insurance, and other risks identified in the Company's Annual Report on Form 10-K for the year ended December 31, 1997, as filed with the Securities and Exchange Commission. CONTACT: Zonagen Inc., The Woodlands Jean Anne Mire, 281/367-5892 KEYWORD: TEXAS INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MEDICINE Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1998, Business Wire